134167-07-0

Usage

Uses

Used in Pharmaceutical Industry:
Boc-Ser-OMe is used as a building block for the synthesis of peptides and proteins, contributing to the development of new pharmaceutical compounds and drug formulations. Its stability and ease of handling make it an ideal candidate for solid-phase peptide synthesis, which is a key technique in the production of complex peptide-based drugs.
Used in Research and Development:
In the field of research and development, Boc-Ser-OMe is used as a tool for studying protein structure and function. Its applications extend to the investigation of protein interactions, enzymatic activities, and the mechanisms of various biological processes, thereby enhancing our understanding of these systems and potentially leading to the discovery of novel therapeutic targets.
Used in Organic Synthesis:
Boc-Ser-OMe is employed in organic synthesis as a versatile reagent and intermediate for the preparation of a wide range of organic compounds. Its unique structure allows for the synthesis of various derivatives and analogs, which can be further utilized in the development of new chemical entities with potential applications in various industries, including pharmaceuticals, agrochemicals, and materials science.
Used in Peptide Synthesis:
Boc-Ser-OMe is used as a key component in the solid-phase peptide synthesis process, where it serves as a protected amino acid building block. Its use in this process facilitates the stepwise assembly of peptide chains, leading to the production of peptides with specific sequences and functions, which are vital for various therapeutic and diagnostic applications.

Upstream product

• 54555-84-9 benzyl iodoethyl ether 
• 3262-72-4 (S)-N-(tert-butoxycarbonyl)serine 
• 74-88-4 methyl iodide 
• 2766-43-0 N-tert-butyloxycarbonyl-L-serine methyl ester 
• 4530-20-5 BOC-glycine 
• 24424-99-5 di-tert-butyl dicarbonate 
• 327051-11-6 O-methyl-L-serine methyl ester hydrochloride 
• 420-37-1 trimethoxonium tetrafluoroborate 
• 67-56-1 methanol 
• 51293-47-1 N-tert-butoxycarbonyl-(S)-O-methyl-serin 

Downstream Products

• 51293-47-1 N-tert-butoxycarbonyl-(S)-O-methyl-serin 
• 161561-84-8 N-Boc-O-methyl-L-serinamide 
• 145296-43-1 (S)-tert-butyl 1-methoxy-3-oxopropan-2-ylcarbamate 
• 183793-49-9 (R)-tert-butyl 1-hydroxy-3-methoxy propan-2-yl carbamate 
• 327051-11-6 O-methyl-L-serine methyl ester hydrochloride 

Relevant academic research and scientific papers

Combining Mass Spectrometric Metabolic Profiling with Genomic Analysis: A Powerful Approach for Discovering Natural Products from Cyanobacteria

An innovative approach was developed for the discovery of new natural products by combining mass spectrometric metabolic profiling with genomic analysis and resulted in the discovery of the columbamides, a new class of di- and trichlorinated acyl amides with cannabinomimetic activity. Three species of cultured marine cyanobacteria, Moorea producens 3L, Moorea producens JHB, and Moorea bouillonii PNG, were subjected to genome sequencing and analysis for their recognizable biosynthetic pathways, and this information was then compared with their respective metabolomes as detected by MS profiling. By genome analysis, a presumed regulatory domain was identified upstream of several previously described biosynthetic gene clusters in two of these cyanobacteria, M. producens 3L and M. producens JHB. A similar regulatory domain was identified in the M. bouillonii PNG genome, and a corresponding downstream biosynthetic gene cluster was located and carefully analyzed. Subsequently, MS-based molecular networking identified a series of candidate products, and these were isolated and their structures rigorously established. On the basis of their distinctive acyl amide structure, the most prevalent metabolite was evaluated for cannabinomimetic properties and found to be moderate affinity ligands for CB1. (Chemical Equation Presented)

Short-chain 3-ketoceramides, strong apoptosis inducers against human leukemia HL-60 cells

Ceramides act as a second messenger of the apoptotic signaling process. The allylic alcohol portion comprising the C-3, C-4, and C-5 carbons is essential for this function. The suggestion has been made that this alcohol moiety is oxidized in mitochondria to a carbonyl moiety, with the generation of reactive oxygen species. However, there is no established precedent for the apoptotic performance of 3-ketoceramides thus presumed. In this work, we have synthesized three different types of short-chain 3-ketoceramides, that is, (2S, 4E)-2-acetylamino-3-oxo-4-octadecen-1-ol (A), (2S, 4E, 6E)-2-acetylamino-3-oxo-4,6-octadecadien-1-ol (B), and (2S, 4E)-2-acetylamino-1-methoxy-3-oxo-4-octadecene (C), and demonstrated that these 3-ketoceramides are capable of inducing effective apoptosis in human leukemia HL-60 cells. In particular, the two monoenoic compounds, A and C, are far more powerful than the corresponding alcoholic analogue, N-acetyl-d-erythro-sphingosine. Observations of DNA fragmentation, caspase-3 activation, and cytochrome c release from mitochondria provide substantiated evidence for mitochondrial apoptosis and the effects of exogenous glutathione on these phenomena are also discussed.

Biosurfactants from Marine Cyanobacteria Collected in Sabah, Malaysia

Chemical investigation of the organic extract from Moorea bouillonii, collected in Sabah, Malaysia, led to the isolation of three new chlorinated fatty acid amides, columbamides F (1), G (2), and H (3). The planar structures of 1-3 were established by a combination of mass spectrometric and NMR spectroscopic analyses. The absolute configuration of 1 was determined by Marfey's analysis of its hydrolysate and chiral-phase HPLC analysis after conversion and esterification with Ohrui's acid, (1S,2S)-2-(anthracene-2,3-dicarboximido)cyclohexanecarboxylic acid. Compound 1 showed biosurfactant activity by an oil displacement assay. Related known fatty acid amides columbamide D and serinolamide C exhibited biosurfactant activity with critical micelle concentrations of about 0.34 and 0.78 mM, respectively.

Synthesis and application of peptide borate compounds

The invention belongs to the field of drug synthesis, and specifically relates to a series of novel peptide borate compounds or pharmaceutical salts thereof, and a preparation method and pharmaceutical application thereof. The structure of the peptide borate compounds or the pharmaceutical salts thereof is as shown in a formula I which is described in the specification. The compounds of the invention can be used for preparing proteasome inhibitors, and thus can be further used for treating solid tumors and blood tumors.

Preparation method of R-2-acylamino-3-methyl methoxypropionate

The invention discloses a preparation method of R-2-acylamino-3-methyl methoxypropionate shown in a formula (I). The preparation method is characterized by comprising the following steps: firstly, enabling N-acyl protected glycine, which is used as a raw material and shown in a formula (II), bis(trichloromethyl) carbonate (III) and N, N-disubstituted formamide shown (IV) to be subjected to a cyclization reaction so as to obtain an intermediate (V); then, carrying out alkali treatment, acid ring-opening and methyl etherification to obtain an intermediate (VII); finally, carrying out asymmetrichydrogenation reduction to generate a target product (I). The preparation method provided by the invention has the advantages that the raw materials are simple and easy to obtain, the cost is low, reaction conditions are mild, the yield is high, the aftertreatment is simple, three wastes are less, and the economic benefit is good, thus being an environment-friendly process suitable for industrialproduction. (The formulas (I), (II), (III), (IV), (V), (VI) and (VII) are shown in the description.).

FUSED MORPHOLINOPYRIMIDINES AND METHODS OF USE THEREOF

The present disclosure relates to Fused Morpholinopyrimidines, pharmaceutical compositions comprising an effective amount of a Fused Morpholinopyrimidine and methods for using a Fused Morpholinopyrimidine in the treatment of a neurodegenerative disease, comprising administering to a subject in need thereof an effective amount of a Fused Morpholinopyrimidine.

Dipeptide boric acid composed of carboxylic acid and alpha-amino acid as well as ester compound thereof, and preparation method and application of dipeptide boric acid and ester compound thereof

The invention belongs to the field of drug synthesis and in particular relates to a series of novel peptide boric acids as well as an ester compound or pharmaceutical salt thereof, and a preparation method and application of the peptide boric acids as well as the ester compound or pharmaceutical salt thereof in pharmacodynamics. A structure of the peptide boric acid and the ester compound or pharmaceutical salt thereof is shown in a formula I (described in the specification). The compound provided by the invention can be used for preparing a proteasome inhibitor and can further be used for treating solid tumours and blood tumours, wherein the solid tumours are selected from non-small cell lung cancer, small cell lung cancer, lung adenocarcinoma, lung squamous carcinoma, pancreatic cancer, breast cancer, prostate cancer, liver cancer, skin cancer, epithelial cell cancer, gastrointestinal stromal tumor, nasopharynx cancer and leukemia; and the blood tumours are selected from multiple myeloma, mantle cell lymphoma and histiocytic lymphoma.

EPOXYKETONE COMPOUNDS FOR ENZYME INHIBITION

The present disclosure relates to novel compounds and pharmaceutical compositions thereof which are useful as inhibitors of proteasomes. The compounds provided herein have improved proteasome potency and selectivity, and increased aqueous solubility, and

Concise synthesis of (+)-serinolamide A

Serinolamide A, isolated from a species of marine cyanobacteria, exhibits a moderate agonist effect and selectivity for the CB1 cannabinoid receptor, which is unusual for marine natural products. Herein, we reported a highly efficient enantiospecific first total synthesis of (+)-serinolamide A from l-serine in nine steps with 30% overall yield. The synthesis method provides a facile, practicable, and economical approach for the preparation of other similar endocanabinoid lipids.

A short and efficient synthesis of (2S,3S,4S)-tert-butyl 3,4-dihydroxy-2-(methoxymethyl)-5-oxopyrrolidine-1-carboxylate

Asymmetric synthesis of the title compound was accomplished starting from l-serine. Stannoxane-mediated lactamization provided the key intermediate in good yield. Georg Thieme Verlag Stuttgart.